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Throughout the body, speciﬁc tissues and cells have evolved individ-
ualizedmetabolic patterns. Tubular epithelial cells in the kidney require
large amounts of energy, mostly to reabsorb ﬁltered electrolytes and toAutosomal dominant polycystic kidney disease (ADPKD) is one of
the most common genetic disorders, occurring in approximately 1 in
every 1000 live births (Wilson, 2004). About 50% of people who inherit
the mutation will develop chronic kidney disease (CKD), characterized
by the development of multiple large cysts in both kidneys followed
by functional decline and end-stage renal disease. While the genetic
mutations in polycystin 1 and polycystin 2 (PKD1 and PKD2, respective-
ly) (Rangan et al., 2015) were identiﬁed more than 30 years ago,
the mechanism of disease development remains largely unknown
(Reeders et al., 1985). Menezes et al. took an unbiased systems-
biology approach to study Pkd1 gene function and report their results
in the current issue of EBioMedicine (Menezes et al., 2016).
The authors performed genome wide transcript proﬁling on mice
with conditional deletion of Pkd1, a model of ADPKD. They noted that
disease severity was much milder in female mice when compared to
their male counterparts. Metabolic genes represented the largest differ-
entially expressed gene cluster, which correlated with disease develop-
ment. Speciﬁcally, they identiﬁed differences in expression levels of
several important regulators of lipid metabolism, which they probed
further with unbiasedmetabolomics and lipidomics studies. Lipidomics
studies highlighted several signiﬁcant differences between control and
Pkd1 knockout animals, including signiﬁcantly lower diacylglycerol
levels in mutant kidneys. Diacylglycerol is a byproduct of triglyceride
metabolism. This prompted the authors to take a closer look at fatty
acid oxidation. Cell culture studies showed that renal epithelial cells
lacking Pkd1 have a cell autonomous defect in fatty acid oxidation, as
these cells not oxidize palmitate as efﬁciently as control cells. Even
though previous studies indicated changes in glucose metabolism in
ADPKD, speciﬁcally an increased reliance on glucose as an energy sourceom.2016.01.027.
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eliminate potential toxins. This process has a high energy demand. Al-
though constituting only 0.5% of body mass, kidneys consume 10% of
the oxygen. To fuel this high energy consumption, tubule epithelial
cells preferentially take up and oxidize fatty acids as their energy source
and have a very high mitochondrial density (Meyer et al., 1997). Gene
expression studies performed onmicrodissected tubule samples obtain-
ed from patients with (diabetic and hypertensive) chronic kidney dis-
ease (CKD) compared to healthy subjects highlighted that fatty acid
metabolism is altered in human CKD samples (Kang et al., 2015). In ad-
dition, cell culture studies indicate that CKD tubule cells are unable to
switch to alternative fuel source such as glucose to efﬁciently generate
energy. When lacking in energy, tubule cells are left dedifferentiated,
unable to perform energy-demanding transport functions. Results of
the present study indicate that the defect in lipidmetabolism is not spe-
ciﬁc for a CKD type and most likely can be seen in all forms CKD.
Future studies should aim to understand molecular alterations ob-
served in the metabolism of CKD kidneys. Are these problems caused
by a defect in a single step in fatty acid oxidation, or multiple steps are
altered due to transcriptional regulatory defect? Current observations
hint that the defect is upstream at the transcriptional regulation of
rate limiting enzymes. Changes can be observed in critical transcription
factors such as PPARA and PPARGC1a. It is likely that these upstream
transcription factors balance energy generationwith energy consuming
cell type-speciﬁc function. This is likely achieved by transcription factor
cooperativity. Future research therefore should focus on understanding
the transcriptional regulatory network that controls the energetics of
renal tubule cells.
Towhat extent do thesemetabolic defects contribute to the progres-
sion of ADPKDand other forms of CKD?While, Menezes et al. did not di-
rectly address the role of lipid metabolism in PKD kidneys, they did
show that even a small (2%) increase in fat in animals' diets worsened
disease severity, potentially indicating that lipids play a role in ADPKD
progression. The contribution of a lipid metabolism defect to other
forms of CKD has already been established. Transgenic expression of
PPARA or its co-activator PPARGC1A ameliorates ﬁbrosis development
induced by toxins (e.g., folic acid) or urethral obstruction, but effectsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cological activation of PPARA or its upstream regulator AMPK has
shown to effectively reduce scarring in mouse ﬁbrosis models. Metfor-
min, a widely used antidiabetic drug and pharmacological activator of
AMPK, has already been shown to reduce cystogenesis in ADPKD animal
model (Takiar et al., 2011), indicating commonalities in the pathway.
On the other hand, these results would also indicate that activation of
PPARA with fenoﬁbrate might actually be beneﬁcial for subjects with
ADPKD. While the use of fenoﬁbrate in the clinic is limited because it
raises serum creatinine level. Clinical studies (FIELD and ACCORD) indi-
cate that it can signiﬁcantly reduce albuminuria and other intermediate
CKD markers in patients with diabetes-associated CKD.
As with many new discoveries, we have more questions than an-
swers. For example, how does mutation in membrane proteins, such
as PKD1 or PKD2, result in a defect in fatty acid oxidation? What is
the role of serum lipids in CKD development? Can we inﬂuence
CKD development in patients by changing the fat composition of
their diet?
In summary, the work byMenezes provides an excellent illustration
of how unbiased high-throughput methods are able to highlight poten-
tially targetable mechanisms in disease pathogenesis. In kidney dis-
eases, integrated data analysis, including transcript and metabolite
proﬁling indicate that proper fatty acid oxidation plays a critical role
in CKD development.Conﬂicts of interest
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